1.1 Why Cancer Diagnosis Is Getting More Complex

• Every year, new, sophisticated diagnostic techniques are developed.
• Almost every neoplasm now has subcategories with distinct morphology, molecular profile, and treatment implications.
• So diagnosis is no longer just “cancer vs no cancer,” but what exact subtype, which directly affects therapy.

Memory tip:

• “Cancer diagnosis = yearly upgrade.”

1.2 Role of Clinicians and Radiologists

Pathologists cannot work in a vacuum.

• Clinicians provide:
• History, physical findings, lab results.
• Radiologists provide:
• Imaging patterns, lesion location, size, number, and relationships.

These are essential for correctly interpreting the specimen.

Examples:

• Radiation-induced skin/mucosal changes may mimic cancer histologically.
• Healing fractures can mimic osteosarcoma on imaging and gross appearance.

So clinical + radiologic context = “roadmap” before the microscope.

Memory tip:

• “Doctors & scans = roadmap before microscope.”

1.3 Specimen Requirements

For an accurate diagnosis:

• The specimen must be:
• Adequate (enough tissue/cells)
• Representative (from the right area)
• Properly preserved (fixation, transport, no crush artifact)

Memory tip:

• “Good specimen = good diagnosis.”

2. Morphologic Methods: Sampling

2.1 Main Sampling Approaches

Three broad ways to obtain material for diagnosis:

1. Excision / Biopsy
• Can be incisional (piece) or excisional (whole lesion).
2. Fine-needle aspiration (FNA)
• Cells aspirated with a fine needle for cytology.
3. Cytologic smears
• Shed or scraped cells onto a slide (e.g., Pap smear).

Memory tip:

• “3 ways to sample: Cut, Needle, Smear.”

2.2 Biopsy of Large Masses – Pitfalls

When biopsying a large mass:

• Periphery vs center:
• The center may be necrotic (dead tissue).
• Margins may show reactive or fibrotic changes.
• A poorly chosen biopsy site can be misleading and not reflect the true nature of the tumor.
• Proper site selection, often guided by imaging, is critical.

Memory tip:

• “Don’t trust the center—it may be dead core.”

3. Frozen Section Diagnosis

3.1 What Is a Frozen Section?

• A piece of tissue is:
• Rapidly frozen
• Thinly sectioned in a cryostat,
• Stained and examined within minutes.
• Used intraoperatively to guide surgical decisions:
• Is this lesion benign or malignant?
• Are margins free of tumor?
• Is a lymph node involved by metastasis?

Memory tip:

• “Freeze now, know now.”

3.2 Limitations of Frozen Sections

• Frozen sections lack the fine histologic detail seen in routine paraffin-embedded sections.
• Artifacts are more common.
• In uncertain cases, it is better to wait for the permanent section than to risk:
• Inadequate surgery
• Unnecessary radical surgery.

Memory tip:

• “Fast but fuzzy.”

4. Fine-Needle Aspiration (FNA)

4.1 Technique and Uses

• A fine needle is inserted into a lesion.
• Cells are aspirated and spread on slides for cytologic evaluation.
• Very useful for palpable lesions like:
• Breast
• Thyroid
• Lymph nodes
• Salivary glands
• Combined with imaging guidance (US/CT), FNA can sample:
• Liver
• Pancreas
• Deep pelvic or abdominal nodes
• Advantages:
• Minimally invasive
• Low risk
• Avoids surgical biopsy in many cases

Memory tip:

• “Needle pulls cells, avoids the knife.”

4.2 Limitations

• Sample size is small.
• Dependent on accurate targeting and experienced cytopathologist.
• Risk of sampling error (missing the malignant area).
• Still, in skilled hands, FNA is rapid and reliable.

Memory tip:

• “Tiny sample, big results if skilled.”

5. Cytologic (Papanicolaou) Smears

5.1 Principle

• Tumor cells are often less cohesive and more likely to shed into:
• Secretions
• Body fluids
• Smears (e.g., Pap smears) collect shed or scraped cells, which are examined for features of anaplasia and dysplasia.

Memory tip:

• “Tumor cells can’t hold hands—so they shed away.”

5.2 Uses and Impact

• Originally developed to detect cervical carcinoma, especially carcinoma in situ.
• Now used for many other sites:
• Cervix, endometrium
• Bronchial tree (bronchogenic carcinoma)
• Bladder, prostate
• Gastric malignancies
• Also useful for detecting malignant cells in:
• Cerebrospinal fluid
• Pleural and peritoneal fluids
• Joint (synovial) fluids

The dramatic reduction in cervical cancer rates globally is the best proof of the value of Pap smear screening.

Memory tip:

• “From cervix to everywhere.”
• “Pap saved the cervix.”

6. Immunohistochemistry (IHC)

6.1 Principle and Role

• IHC uses monoclonal antibodies directed against specific cell markers (antigens).
• These antibodies are visualized using chromogens → tumor cells light up in specific patterns.
• Helps:
• Determine cell lineage
• Classify undifferentiated tumors
• Identify primary sites of metastases
• Predict response to targeted therapy.

Memory tip:

• “Antibodies as diagnostic paint.”

6.2 Classic Examples

• Cytokeratin:
• Marker of epithelial cells.
• Positive in carcinomas, helping to distinguish them from lymphomas or sarcomas.
• Prostate-specific antigen (PSA):
• Identifies tumors of prostatic origin in metastases.
• Estrogen receptor (ER) in breast carcinoma:
• Helps with prognosis.
• Guides hormone therapy decisions.

Memory tip:

• “Markers = cancer’s nametag.”

7. Flow Cytrometry

7.1 Principle

• Cells are labeled with fluorescent-tagged antibodies against:
• Surface molecules
• Differentiation antigens (CD markers)
• They pass single-file through a laser beam.
• The instrument measures:
• Fluorescence
• Size and complexity
• Output provides a phenotypic profile of the cell population.

Memory tip:

• “Laser counts and labels cells.”

7.2 Main Uses

• Extensively used in hematologic malignancies, especially:
• Leukemias
• Lymphomas
• Helps classify:
• T vs B vs NK lineage
• Maturation stage
• Clonality patterns.

Memory tip:

• “Flow = blood cancers.”

8. Tumor Markers

8.1 General Role and Limitations

• Tumor markers are substances produced by tumor cells (or induced in host tissues) that can be measured in blood or other body fluids.
• Examples: PSA, CEA, AFP.
• They are not reliable for definitive diagnosis because:
• They have low sensitivity and low specificity.
• Levels can be elevated in benign conditions.
• No cut-off guarantees absence of cancer.

Main uses:

• Screening aid in selected high-risk groups (with caution).
• Monitoring response to therapy.
• Detecting recurrence (rising levels after treatment).

Memory tip:

• “Not for yes/no, but good for follow-up.”
• “Tumor markers = noisy signals.”

8.2 PSA – Prostate-Specific Antigen

• Marker for prostatic adenocarcinoma.

Uses and Controversy

• Elevated in:
• Prostate cancer
• Benign prostatic hyperplasia (BPH)
• Prostatitis
• No PSA value completely excludes cancer.
• Therefore, controversial as a screening tool in asymptomatic men.

Best Use

• Very valuable for:
• Detecting residual disease
• Monitoring recurrence after prostate cancer treatment.

Memory tips:

• “PSA = Prostate’s Signal Alert.”
• “PSA = Problematic Screening Assay.”
• “PSA best for tracking comeback.”

8.3 CEA – Carcinoembryonic Antigen

• Produced by:
• Carcinomas of colon
• Pancreas
• Stomach
• Breast

Clinical Utility

• Not specific enough for screening.
• Useful for monitoring known cancer:
• Levels fall after successful tumor resection.
• Reappearance or rise → recurrence or metastasis.
• Also elevated in various non-neoplastic conditions, further lowering specificity.

Memory tips:

• “CEA = Cancers of Colon & Company.”
• “CEA comeback = cancer comeback.”
• “CEA = Can Elevate Anyway.”

8.4 AFP – Alpha Fetoprotein

• Produced by:
• Hepatocellular carcinoma
• Yolk sac tumors of gonads
• Sometimes teratocarcinomas and embryonal carcinomas

Uses

• Like CEA, not reliable for early detection.
• Helpful for monitoring disease:
• Levels disappear after successful resection or treatment.
• Reappearance suggests relapse.

Memory tips:

• “AFP = Adult liver, Fetal parts.”
• “AFP fades after fix, returns with relapse.”

Shared Drawback of PSA, CEA, AFP

• All:
• Lack high sensitivity and specificity.
• Elevated in benign and malignant conditions.
• Best for monitoring rather than primary screening.

Memory tip:

• “Tumor markers = follow-up friends, not first finders.”

9. Molecular Diagnosis of Cancer

9.1 Distinguishing Neoplastic vs Reactive Proliferations

PCR for Clonality

• Each T and B cell has a unique rearrangement of its antigen receptor genes.
• Reactive lymphoid proliferations = polyclonal.
• Neoplastic lymphoid proliferations = monoclonal.
• PCR can detect:
• Monoclonal vs polyclonal rearrangement patterns → helps distinguish lymphoma from reactive hyperplasia.

Memory tip:

• “PCR = poly vs clonal reader.”

Translocation Detection

• Many tumors have characteristic chromosomal translocations:
• Ewing sarcoma
• Leukemias and lymphomas
• BCR-ABL transcript → confirms chronic myeloid leukemia (CML).
• These can be detected by:
• PCR
• FISH

Memory tip:

• “Translocation = tumor’s fingerprint.”

JAK2 Mutation in Myeloproliferative Neoplasms

• Polycythemia vera is strongly associated with:
• Point mutations in JAK2, a nonreceptor tyrosine kinase.
• This mutation helps confirm diagnosis.

Memory tip:

• “PV = JAKed up blood.”

9.2 Prognosis and Tumor Behavior

Molecular tests can provide prognostic information by detecting:

• Oncogene amplifications:
• HER2 amplification in breast cancer
• NMYC amplification in neuroblastoma
• Tumor suppressor gene mutations:
• TP53 mutations → generally poor prognosis in many cancers.
• Molecular assessment of immune response:
• Presence of cytotoxic T-cell infiltrates can correlate with better outcomes in some tumors.

Memory tip:

• “Genes tell future, T-cells tell fight.”

9.3 Detection of Minimal Residual Disease (MRD)

After treatment:

• PCR can detect very low levels of:
• BCR-ABL transcripts in CML → sign of persistent disease.
• Circulating tumor cells and circulating tumor DNA (ctDNA):
• Can be measured to track tumor burden and relapse.

Memory tip:

• “Tiny tumor traces tracked by PCR.”

9.4 Hereditary Predisposition

• Germline mutations in tumor suppressor genes (e.g., BRCA1 and BRCA2) confer a high lifetime risk of certain cancers.
• Identifying these:
• Allows aggressive screening.
• Enables prophylactic surgery (e.g., risk-reducing mastectomy/oophorectomy).
• Facilitates family counseling.

Memory tip:

• “BRCA = BRings CAncer risk.”

9.5 Guiding Targeted Therapy

Molecular testing identifies actionable mutations → directs use of targeted drugs.

Example: BRAF V600E

• A point mutation in BRAF:
• Valine → glutamate at codon 600 (V600E).
• Found in:
• Many melanomas (classic)
• Some cancers of colon, thyroid
• Hairy cell leukemia
• Langerhans cell histiocytosis
• Tumors with BRAF V600E often respond well to BRAF inhibitors.

Memory tips:

• “BRAF V600E = breakthrough drug target.”
• “Different clothes, same engine.”

10. Molecular Profiling of Tumors (“Omics”)

10.1 What Is “Omics”?

• Genome – DNA sequence.
• Epigenome – DNA/histone modifications.
• Transcriptome – RNA expression profile (which genes are active).
• Proteome – proteins present.
• Metabolome – metabolite pattern.

These layers together give a comprehensive molecular portrait of a tumor.

Memory tip:

• “Omics = all the layers of the cell.”

10.2 Evolution of Cancer Study

• Historically: looked at single genes.
• Now: large-scale profiling of many genes, RNAs, proteins at once.
• Diagnosis, prognosis, and therapy increasingly rely on these profiles.

Memory tip:

• “From single tree to whole forest.”

10.3 RNA and DNA Sequencing

Older RNA Method: Microarrays

• DNA microarrays used to measure RNA expression.
• Being replaced by RNA sequencing (RNA-seq).

RNA Sequencing

• More comprehensive and quantitative.
• Challenge: RNA is fragile and prone to degradation → harder to handle.

Memory tip:

• “RNA-seq = clear voice but fragile.”

DNA Sequencing

• Technically simpler and more robust.
• Basis for massively parallel (next-generation) sequencing.
• Works on almost any tissue specimen (fresh, frozen, formalin-fixed).

Memory tip:

• “DNA = sturdy book; RNA = fragile paper.”

10.4 Next-Generation Sequencing (NGS) and TCGA

• Human Genome Project (finished around 2003) took:
• 12 years and about $2.7 billion.
• Now:
• A tumor genome can be sequenced in weeks for less than $5000.
• The Cancer Genome Atlas (TCGA):
• Catalogues genomic alterations in many cancer types.
• Reveals:
• New recurrent mutations
• Full mutation spectra
• Intratumoral heterogeneity (multiple clones inside one tumor).

Memory tips:

• “From billions + decade → to thousands + weeks.”
• “TCGA = cancer’s library.”

10.5 Clinical Use of Sequencing

• Whole-genome sequencing for every patient is not routine:
• Too costly
• Too complex for everyday use
• Instead, clinicians focus on:
• Targeted sequencing of “actionable” mutations.
• Particularly useful for genetically diverse cancers like:
• Lung carcinoma, where therapy must be tailored to specific mutations (EGFR, ALK, ROS1, BRAF, etc.).

Memory tips:

• “Not whole book, just key chapters.”
• “Lungs need custom key.”

Depth of Sequencing

• Tumor samples are often heterogeneous.
• To detect mutations present in as little as 5% of tumor cells, sequencing must be done at sufficient depth (high coverage).

Memory tip:

• “Depth = fishing out rare 5% fish.”

10.6 DNA Arrays and Copy Number Changes

• DNA arrays can detect:
• Copy number gains (amplifications)
• Deletions
• These complement sequencing by showing:
• Which chromosomal regions are lost or expanded.

Memory tip:

• “Arrays = zoom-out view.”

10.7 Proteomics and Epigenomics

• Proteomics and epigenomics currently play a bigger role in research, but:
• Drugs targeting the cancer epigenome (e.g., DNMT inhibitors, HDAC inhibitors) are entering clinical practice.
• This will drive development of predictive epigenomic tests.

Memory tip:

• “Epigenome drugs = switches and locks.”

10.8 Histopathology vs Molecular Profiling

• Molecular profiling will not replace traditional histopathology.
• Histology remains crucial for:
• Degree of anaplasia
• Invasiveness
• Heterogeneity of tumor cells
• Tumor–stroma interactions:
• Angiogenesis
• Immune infiltrates
• Desmoplasia
• Best practice = combine:
• Morphologic data (microscope)
• Molecular data (sequencer)

Memory tip:

• “Microscope + sequencer = full picture.”

10.9 Future Outlook

• Cancer diagnostics is moving towards:
• Integrated pathology (morphology + multi-omics).
• Highly personalized therapy based on each tumor’s molecular profile.
• Rapid advances are expected within the current generation of clinicians.

Memory tip:

• “Golden age of cancer diagnosis.”

If you want, next I can:

• Convert this whole note into XMind-style markdown for direct mind map use, or
• Generate a Step 1 SBA/MCQ set just based on Lab diagnosis + Tumor markers + Molecular Dx + Omics.